Terms ending in 2026
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,514,223 | Cross-Screening System and Methods for Detecting a Molecule Having Binding Affinity for a Target Molecule In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 7,763,245 | Methods and Compositions for Targeting Polyubiquitin In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 7,812,133 | ANTI-OX40L Antibodies and Methods Using Same In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,906,648 | Recombinant Production of Vascular Endothelial Growth Factor In force · High confidence | Genentech, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.